(R) -Roscovitine

(R) -Roscovitine (Seliciclib) is an orally bioavailable and selective CDKs inhibitor with IC50s of 0.2 μM, 0.65 μM, and 0.7 μM for CDK5, Cdc2, and CDK2, respectively.

Product Specifications

CAS Number

[186692-46-6]

Product Name Alternative

Seliciclib; CYC202

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

CDK

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/r-roscovitine.html

Purity

99.53

Solubility

DMSO : ≥ 100 mg/mL

Smiles

OC[C@H](NC1=NC(NCC2=CC=CC=C2)=C3C(N(C=N3)C(C)C)=N1)CC

Molecular Formula

C19H26N6O

Molecular Weight

354.45

Precautions

H302, H315, H319, H335

References & Citations

[1]Meijer L, et al. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. Eur J Biochem. 1997 Jan 15;243 (1-2) :527-36.|[2]Bai X, et al. CDK5 promotes renal tubulointerstitial fibrosis in diabetic nephropathy via erk1/2/pparγ pathway. Oncotarget. 2016 Apr 27.|[3]Gary C, et al. Selective antitumor activity of roscovitine in head and neck cancer. Oncotarget. 2016 May 23.